Faron presents BEXMAB data at ASH Annual Meeting ...Middle East

Faron Pharmaceuticals Ltd. ("Faron" or "the Company") Faron Presents Full Analysis of Positive Phase 2 Interim Data from BEXMAB Trial at the 66th American Society of Hematology (ASH) Annual Meeting Poster highlights Overall response rate of 80% (16 out of 20) in refractory or relapsed HMA...

Hence then, the article about faron presents bexmab data at ash annual meeting was published today ( Tuesday 10/12/2024 - 10:53 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Faron presents BEXMAB data at ASH Annual Meeting )

Also on site :

• Enbridge aims to help North America win from the AI boom and the Iran war as the FedEx of energy delivery
• Quote of the Day: Organizational Psychologist Adam Grant on Rethinking Self-Doubt and Building Confidence
• Stellantis N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - STLA